Mechanisms of Lipodystrophy in HIV-Infected Pateints
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The metabolic and molecular basis of lipodystrophy syndrome in HIV-infected patients is not
known. Whether besides protease inhibitors, other antiretroviral drugs, HIV infection and
reduction in viral load contribute to the development of lipodystrophy syndrome is not clear.
The project therefore has the following aims: 1) to characterize metabolic abnormalities and
changes in body fat distribution, 2) to develop objective criteria for defining the syndrome
and to ascertain prognostic indicators and 3) to elucidate the molecular basis of the
lipodystrophy syndrome in HIV-infected patients.